Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals Plc director Stephen Barry Parker filed an initial statement of ownership showing holdings of a stock option over 576 American Depositary Shares. The option has an exercise price of $475.0000 per ADS and expires on January 23, 2034.
The shares underlying this option vest over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to his continued service. Each American Depositary Share represents 100,000 ordinary shares of Biodexa.
Biodexa Pharmaceuticals is changing the ratio of its American Depositary Receipts to consolidate ADRs and support compliance with Nasdaq listing rules. Each ADR will shift from representing 100,000 ordinary shares to representing 500,000 ordinary shares, with the change expected to take effect on or about April 6, 2026.
ADR holders must surrender their existing ADRs and will receive one new ADR for every five old ADRs. No fractional ADRs will be issued; any aggregated fractions will be sold and the net cash distributed to entitled holders. This operates like a one-for-five reverse ADR split and does not affect the underlying ordinary shares. The company states the change is intended to help its ADR price meet Nasdaq’s $1.00 minimum bid requirement but gives no assurance this objective will be achieved.
Biodexa Pharmaceuticals Plc director Ann Louise Merchant reported an initial holding of a stock option over 288 American Depositary Shares, with an exercise price of $475.00 per ADS and an expiration date of January 23, 2034. The option vests over four years, starting with 25% after one year and 6.25% every three months thereafter, so long as she continues in service.
Biodexa Pharmaceuticals Plc Chief Executive Officer Stephen Anthony Stamp filed an initial Form 3 reporting his beneficial ownership of stock options. He holds options to buy 859 American Depositary Shares at an exercise price of $327.5000 per ADS expiring in 2034, and options over 1,500, 25,000 and 15,000 Ordinary Shares at exercise prices of $28.0500, $7.4100 and $5.4000 per share, with expirations between 2029 and 2031. The filing lists existing option awards and does not show any new purchases or sales.
Biodexa Pharmaceuticals director Simon de Vries filed an initial ownership report showing a stock option holding. The option covers 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The underlying shares vest over four years, with 25% vesting after one year and the remainder vesting quarterly, subject to continued service.
Biodexa Pharmaceuticals Plc filed an initial insider report listing stock option holdings for Chief Financial Officer Fiona Mary Powell. The filing shows three option grants: one over 286 American Depositary Shares with a $327.5000 exercise price expiring on February 10, 2034, and two over ordinary shares covering 7,500 and 8,750 shares with exercise prices of $5.4000 and $7.4100, expiring on June 16, 2030 and July 14, 2031 respectively. Footnotes explain vesting schedules, note that some shares are already fully vested and exercisable, and clarify that each American Depositary Share represents 100,000 ordinary shares.
Biodexa Pharmaceuticals director Simon Turton has filed an initial ownership report for company securities. The filing shows a stock option over 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The option vests over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to continued service. Turton also reports direct ownership of 2,765 Ordinary Shares. Each American Depositary Share represents 100,000 Ordinary Shares of Biodexa Pharmaceuticals.
Biodexa Pharmaceuticals Plc reports a Schedule 13G showing Armistice Capital, LLC and Steven Boyd beneficially own 283,502 ADS, representing 9.99% of the class as of 12/31/2025. The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager and Steven Boyd is managing member. The Reporting Persons report shared voting and dispositive power of 283,502 ADS and no sole voting or dispositive power. The Master Fund is identified as the direct holder and noted as having the right to receive dividends or sale proceeds.
Biodexa Pharmaceuticals PLC is registering for resale up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares held by selling shareholders, and is updating investors via a prospectus supplement and attached Form 6-K.
The company also reports an exclusive license and collaboration agreement with Otsuka Pharmaceutical, granting Biodexa rights outside Japan to develop, manufacture and commercialize MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors. Biodexa will handle development, manufacturing and commercialization in its licensed territory, with Otsuka eligible for an upfront payment, development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of certain sublicense income.
Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale by existing shareholders of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares. The supplement incorporates a new report describing a strategic licensing transaction.
The company entered an exclusive collaboration with Otsuka Pharmaceutical, obtaining worldwide rights outside Japan to develop, manufacture and commercialize MTX240 (OPB-171775), a Phase 1-ready molecular glue for gastrointestinal stromal tumors. Otsuka receives an upfront payment, potential development and regulatory milestones, and tiered mid-single-digit royalties on net sales, with MTX240 protected by composition of matter patents extending through 2037.